Alerts will be sent to your verified email
Verify Email
ERIS
|
Eris Lifesciences
|
Pfizer
|
Astrazeneca Pharma I
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
6.1 % | 4.8 % | 18.6 % |
|
R&D as a % of Total Sales
|
0.0 | n/a | 0.0 |
|
Financials
|
|||
|
5 yr Average ROE
|
17.74 % | 19.03 % | 17.42 % |
|
5yr average Equity Multiplier
|
1.76 | 1.25 | 1.99 |
|
5yr Average Asset Turnover Ratio
|
0.51 | 0.6 | 0.91 |
|
5yr Avg Net Profit Margin
|
22.76 % | 26.04 % | 9.65 % |
|
Price to Book
|
7.5 | 5.98 | 28.2 |
|
P/E
|
55.76 | 27.4 | 113.16 |
|
5yr Avg Cash Conversion Cycle
|
-54.68 Days | 21.86 Days | -6.33 Days |
|
Inventory Days
|
27.48 Days | 49.93 Days | 68.19 Days |
|
Days Receivable
|
54.07 Days | 29.1 Days | 35.81 Days |
|
Days Payable
|
148.48 Days | 77.28 Days | 187.52 Days |
|
5yr Average Interest Coverage Ratio
|
66.44 | 185.18 | 142.38 |
|
5yr Avg ROCE
|
18.34 % | 23.84 % | 23.84 % |
|
5yr Avg Operating Profit Margin
|
34.43 % | 31.72 % | 14.57 % |
|
5 yr average Debt to Equity
|
0.46 | 0.0 | 0.0 |
|
5yr CAGR Net Profit
|
-0.19 % | 76.68 % | 4.4 % |
|
5yr Average Return on Assets
|
12.4 % | 15.25 % | 8.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.85 % | 63.92 % | 75.0 % |
|
Share Pledged by Promoters
|
16.92 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
2.56 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
6.95 % | 5.23 % | 3.91 % |
|
Eris Lifesciences
|
Pfizer
|
Astrazeneca Pharma I
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Entity Wise Breakup
|
Entity Wise Breakup
|
-
|
-
|
|
EBITDA - Entity Wise
|
EBITDA - Entity Wise
|
-
|
-
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|